LV12375B - 1-(3-aminoindazol-5-il)-fenilmetil)-cikliskas urīnvielas piemērotas kā hiv proteāzes inhibitori - Google Patents
1-(3-aminoindazol-5-il)-fenilmetil)-cikliskas urīnvielas piemērotas kā hiv proteāzes inhibitori Download PDFInfo
- Publication number
- LV12375B LV12375B LVP-99-76A LV990076A LV12375B LV 12375 B LV12375 B LV 12375B LV 990076 A LV990076 A LV 990076A LV 12375 B LV12375 B LV 12375B
- Authority
- LV
- Latvia
- Prior art keywords
- compound
- formula
- hiv
- quot
- reverse transcriptase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (20)
- LV 12375 IZGUDROJUMA FORMULA 1. Savienojums ar formulu I vai IIvai šī savienojuma farmaceitiski pieņemams sāls vai priekštečvielas forma.
- 2. Savienojums saskaņā ar 1. punktu, kas atšķiras ar to, ka šis savienojums atbilst formulai I.
- 3. Savienojums saskaņā ar 1. punktu, kas atšķiras ar to, ka šis savienojums atbilst formulai II.
- 4. Farmaceitiska kompozīcija, kurā ietilpst farmaceitiski pieņemams nesējs un savienojuma saskaņā ar 1. punktu vai šī savienojuma farmaceitiski pieņemama sāls vai priekštečvielas formas terapeitiski efektīvs daudzums.
- 5. Kompozīcija saskaņā ar 4. punktu, kas atšķiras ar to, ka savienojums atbilst formulai I.
- 6. Kompozīcija saskaņā ar 4. punktu, kas atšķiras ar to, ka savienojums atbilst formulai II.
- 7. Savienojuma ar formulu I vai III II vai šī savienojuma farmaceitiski pieņemama sāls vai priekštečvielas formas pielietojums medikamenta iegūšanai HIV (humānā imūndeficīta vīrusa) infekcijas ārstēšanai saimniekiem, kuriem nepieciešama šī ārstēšana.
- 8. Pielietojums saskaņā ar 7. punktu, kas atšķiras ar to, ka savienojums atbilst formulai I.
- 9. Pielietojums saskaņā ar 7. punktu, kas atšķiras ar to, ka savienojums atbilst formulai II.
- 10. Kombinācijas (a) un (b) pielietojums medikamenta iegūšanai HIV infekcijas ārstēšanai, kas atšķiras ar to, ka (a) ir savienojums ar formulu I vai IIi vai šī savienojuma farmaceitiski pieņemams sāls vai priekštečvielas forma; un (b) ir vismaz viens savienojums, kuru izvēlas no grupas, kas sastāv no HIV atgriezeniskās transkriptāzes inhibitoriem un HIV proteāzes inhibitoriem.
- 11.Pielietojums saskaņā ar 10. punktu, kas atšķiras ar to, ka savienojums atbilst formulai I. LV 12375
- 12. Pielietojums saskaņā ar 10. punktu, kas atšķiras ar to, ka savienojums atbilst formulai II.
- 13. Pielietojums saskaņā ar 10. punktu, kas atšķiras ar to, ka atgriezeniskās transkriptāzes inhibitors ir nukleozīda atgriezeniskās transkriptāzes inhibitors.
- 14. Pielietojums saskaņā ar 13. punktu, kas atšķiras ar to, ka nukleozīda atgriezeniskās transkriptāzes inhibitoru izvēlas no AZT, 3TC, ddl, ddC un d4T un proteāzes inhibitoru izvēlas no sahinavīra, ritonavīra, indinavīra, VX-478, nelfinavīra, KNI-272, CGP-61755 un U-103017.
- 15. Pielietojums saskaņā ar 14. punktu, kas atšķiras ar to, ka nukleozīda atgriezeniskās transkriptāzes inhibitoru izvēlas no AZT un 3TC un proteāzes inhibitoru izvēlas no sahinavīra, ritonavīra un indinavīra.
- 16. Pielietojums saskaņā ar 15. punktu, kas atšķiras ar to, ka nukleozīda atgriezeniskās transkriptāzes inhibitors ir AZT.
- 17. Pielietojums saskaņā ar 15. punktu, kas atšķiras ar to, ka proteāzes inhibitors ir indinavīrs.
- 18. Farmaceitisks komplekts, kas piemērots HIV infekcijas ārstēšanai, kurā ietilpst (a) savienojuma saskaņā ar 1. punktu; un (b) vismaz viena savienojuma, kuru izvēlas no grupas, kas sastāv no HIV atgriezeniskās transkriptāzes inhibitoriem un HIV proteāzes inhibitoriem terapeitiski efektīvs daudzums vienā vai vairākos sterilos flakonos.
- 19. Komplekts saskaņā ar 18. punktu, kas atšķiras ar to, ka komponents (a) atbilst savienojumam ar formulu I.
- 20. Komplekts saskaņā ar 18. punktu, kas atšķiras ar to, ka komponents (a) atbilst savienojumam ar formulu II.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74710496A | 1996-11-08 | 1996-11-08 | |
| US2974596P | 1996-11-08 | 1996-11-08 | |
| PCT/US1997/020035 WO1998020008A1 (en) | 1996-11-08 | 1997-11-04 | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12375A LV12375A (lv) | 1999-11-20 |
| LV12375B true LV12375B (lv) | 2000-04-20 |
Family
ID=26705293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-99-76A LV12375B (lv) | 1996-11-08 | 1999-04-29 | 1-(3-aminoindazol-5-il)-fenilmetil)-cikliskas urīnvielas piemērotas kā hiv proteāzes inhibitori |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0937067B1 (lv) |
| JP (1) | JP2001503428A (lv) |
| KR (1) | KR20000053122A (lv) |
| CN (1) | CN1235602A (lv) |
| AT (1) | ATE244714T1 (lv) |
| AU (1) | AU5165198A (lv) |
| BR (1) | BR9712910A (lv) |
| CA (1) | CA2270966A1 (lv) |
| CZ (1) | CZ157599A3 (lv) |
| DE (1) | DE69723456T2 (lv) |
| EA (1) | EA199900452A1 (lv) |
| EE (1) | EE9900188A (lv) |
| ES (1) | ES2202645T3 (lv) |
| HU (1) | HUP9904676A2 (lv) |
| IL (1) | IL129727A0 (lv) |
| LV (1) | LV12375B (lv) |
| NO (1) | NO992228L (lv) |
| PL (1) | PL333421A1 (lv) |
| SI (1) | SI20074A (lv) |
| SK (1) | SK59699A3 (lv) |
| WO (1) | WO1998020008A1 (lv) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0973767A1 (en) * | 1997-03-31 | 2000-01-26 | Dupont Pharmaceuticals Company | Indazoles of cyclic ureas useful as hiv protease inhibitors |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| PL1981851T3 (pl) | 2006-01-31 | 2012-07-31 | Array Biopharma Inc | Inhibitory kinazy i sposoby ich stosowania |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5610294A (en) * | 1991-10-11 | 1997-03-11 | The Du Pont Merck Pharmaceutical Company | Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors |
| US5532357A (en) * | 1995-06-07 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Method for preparing N-monosubstituted and N,N'-disubstituted unsymmetrical cyclic ureas |
-
1997
- 1997-11-04 EE EEP199900188A patent/EE9900188A/xx unknown
- 1997-11-04 PL PL97333421A patent/PL333421A1/xx unknown
- 1997-11-04 BR BR9712910A patent/BR9712910A/pt not_active Application Discontinuation
- 1997-11-04 AT AT97946494T patent/ATE244714T1/de not_active IP Right Cessation
- 1997-11-04 AU AU51651/98A patent/AU5165198A/en not_active Abandoned
- 1997-11-04 IL IL12972797A patent/IL129727A0/xx unknown
- 1997-11-04 JP JP52168198A patent/JP2001503428A/ja active Pending
- 1997-11-04 SI SI9720072A patent/SI20074A/sl unknown
- 1997-11-04 WO PCT/US1997/020035 patent/WO1998020008A1/en not_active Application Discontinuation
- 1997-11-04 CZ CZ991575A patent/CZ157599A3/cs unknown
- 1997-11-04 ES ES97946494T patent/ES2202645T3/es not_active Expired - Lifetime
- 1997-11-04 EA EA199900452A patent/EA199900452A1/ru unknown
- 1997-11-04 EP EP97946494A patent/EP0937067B1/en not_active Expired - Lifetime
- 1997-11-04 HU HU9904676A patent/HUP9904676A2/hu unknown
- 1997-11-04 SK SK596-99A patent/SK59699A3/sk unknown
- 1997-11-04 KR KR1019990704048A patent/KR20000053122A/ko not_active Application Discontinuation
- 1997-11-04 CA CA002270966A patent/CA2270966A1/en not_active Abandoned
- 1997-11-04 DE DE69723456T patent/DE69723456T2/de not_active Expired - Fee Related
- 1997-11-04 CN CN97199419A patent/CN1235602A/zh active Pending
-
1999
- 1999-04-29 LV LVP-99-76A patent/LV12375B/lv unknown
- 1999-05-07 NO NO992228A patent/NO992228L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU5165198A (en) | 1998-05-29 |
| EA199900452A1 (ru) | 2000-02-28 |
| DE69723456D1 (de) | 2003-08-14 |
| EP0937067B1 (en) | 2003-07-09 |
| SK59699A3 (en) | 1999-12-10 |
| PL333421A1 (en) | 1999-12-06 |
| EP0937067A1 (en) | 1999-08-25 |
| JP2001503428A (ja) | 2001-03-13 |
| SI20074A (sl) | 2000-04-30 |
| HUP9904676A2 (hu) | 2000-06-28 |
| DE69723456T2 (de) | 2004-05-27 |
| ATE244714T1 (de) | 2003-07-15 |
| KR20000053122A (ko) | 2000-08-25 |
| ES2202645T3 (es) | 2004-04-01 |
| WO1998020008A1 (en) | 1998-05-14 |
| CZ157599A3 (cs) | 1999-11-17 |
| CN1235602A (zh) | 1999-11-17 |
| BR9712910A (pt) | 2000-03-21 |
| IL129727A0 (en) | 2000-02-29 |
| NO992228L (no) | 1999-06-07 |
| CA2270966A1 (en) | 1998-05-14 |
| EE9900188A (et) | 1999-12-15 |
| NO992228D0 (no) | 1999-05-07 |
| LV12375A (lv) | 1999-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6825210B2 (en) | Tricyclic compounds useful as HIV reverse transcriptase inhibitors | |
| US5932570A (en) | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors | |
| US6391919B1 (en) | Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors | |
| EP0937067B1 (en) | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors | |
| US6313110B1 (en) | Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor | |
| US6218386B1 (en) | A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor | |
| AU722489B2 (en) | (4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor | |
| AU2725700A (en) | Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors | |
| US6562848B1 (en) | Bis-amino acid sulfonamides as HIV protease inhibitors | |
| WO2004013110A1 (en) | 4,4-disubstituted-3,4-dihydro-2(1h)-quinazoliniones useful as hiv reverse transcriptase inhibitors | |
| WO2004043911A2 (en) | N-cycloalkylglycines as hiv protease inhibitors | |
| US7015214B2 (en) | Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazepine as HIV reverse transcriptase inhibitors | |
| MXPA99004286A (en) | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors | |
| HRP970586A2 (en) | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors | |
| MXPA99004294A (en) | (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor | |
| MXPA01007047A (en) | Bis-amino acid sulfonamides containing n-terminally a substituted benzyl group as hiv protease inhibitors | |
| HRP970595A2 (en) | 1-(3-aminoindazol-5-yl)-3-butyl-cyclic urea useful as a hiv proteaze inhibitor | |
| AU2002254652A1 (en) | Tricyclic compounds useful as HIV reverse transcriptase inhibitors |